Антисептики для обработки ран: обзор, сравнение, выбор. Таблица для скачивания

1. Привольнев В. В., Зубарева Н. А., Каракулина Е. В. Местное лечение раневой инфекции: антисептики или антибиотики? //Клиническая микробиология и антимикробная химиотерапия. – 2017. – Т. 19. – №. 2. – С. 131-138 2. Привольнев Владислав Владимирович, Каракулина Е.В. Основные принципы местного лечения ран и раневой инфекции // КМАХ. 2011. №3 3. Medical Microbiology, 8th ed.; Murray, P.; Rosenthal, K.; Pfaller, M.; Elsevier: Amsterdam, The Netherlands, 2020. 4. Polymeric Iodophors: Preparation, Properties, and Biomedical Applications; Makhayeva DN, Irmukhametova GS, Khutoryanskiy VV. Rev J Chem. 2020;10(1):40-57. 5. Joseph Lister: Father of Modern Surgery; Pitt, D.; Aubin, J.-M. Can. J. Surg. 2012, 55, E8–E9. 6. Antisepsis and Asepsis and How They Shaped Modern Surgery; Nakayama, D.K. Am. Surg. 2018, 84, 766–771. 7. The Antimicrobial Effectiveness of Antiseptics as a Challenge in Hard to Heal Wounds; Karpiński, T.; Sopata, M.; Mańkowski, B. Leczenie Ran 2020, 17, 88–94. 8. Wounds—From Physiology to Wound Dressing; Kujath, P.; Michelsen, A. Dtsch. Arztebl. Int. 2008, 105, 239–248. 9. Antimicrobial Stewardship of Antiseptics That Are Pertinent to Wounds: The Need for a United Approach; Maillard, J.-Y.; Kampf, G.; Cooper, R. JAC Antimicrob. Resist. 2021, 3, dlab02. 10. Cytotoxicity and Proliferative Effects of Iodoform-Containing Root Canal-Filling Material on RAW 264.7 Macrophage and RKO Epithelial Cell Lines; Petel, R.; Moskovitz, M.; Tickotsky, N.; Halabi, A.; Goldstein, J.; Houri-Haddad, Y. Arch. Oral. Biol. 2013, 58, 75–81. 11. Endoflas FS Decreases the Viability and Mineralisation Process in Human Alveolar Osteoblastic Cells; Cifuentes-Mendiola, S.; Barrera-Francisco, M.; Garcia-Navarro, M.; Llamosas-Hernandez, E.; Perez-Martinez, I.; Garcia-Hernandez, A. J. Clin. Diagn. Res. 2018, 12, ZC30–ZC33. 12. Rutala, W.A.; Weber, D.J. Healthcare Infection Control Practices Advisory Committee (HICPAC). In Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008; CDC: Atlanta, GA, USA, 2008. 13. Evaluation of Ag@TiO2/WO3 Heterojunction Photocatalyst for Enhanced Photocatalytic Activity towards Methylene Blue Degradation; Basumatary, B.; Basumatary, R.; Ramchiary, A.; Konwar, D. Chemosphere 2022, 286, 131848. 14. Cell-Transforming Activity of Fourteen Chemical Agents Used in Dental Practice in Syrian Hamster Embryo Cells; Yamaguchi, F.; Tsutsui, T. J. Pharmacol. Sci. 2003, 93, 497–500. 15. The Potential for Human Exposure, Direct and Indirect, to the Suspected Carcinogenic Triphenylmethane Dye Brilliant Green from Green Paper Towels; Oplatowska, M.; Donnelly, R.F.; Majithiya, R.J.; Glenn Kennedy, D.; Elliott, C.T. Food Chem. Toxicol. 2011, 49, 1870–1876. 16. Carcinogenicity of Gentian Violet, Leucogentian Violet, Malachite Green, Leucomalachite Green, and CI Direct Blue 218; IARC Monographs Vol 129 Group. Lancet Oncol. 2021, 22, 585–586. 17. Analysis of Trace Malachite Green, Crystal Violet, and Their Metabolites in Zebrafish by Surface-Coated Probe Nanoelectrospray Ionization Mass Spectrometry; Xiao, X.; Chen, C.; Deng, J.; Wu, J.; He, K.; Xiang, Z.; Yang, Y. Talanta 2020, 217, 121064. 18. Efficacy of Antiseptics Containing Povidone-Iodine, Octenidine Dihydrochloride and Ethacridine Lactate against Biofilm Formed by Pseudomonas Aeruginosa and Staphylococcus Aureus Measured with the Novel Biofilm-Oriented Antiseptics Test; Junka, A.; Bartoszewicz, M.; Smutnicka, D.; Secewicz, A.; Szymczyk, P. Int. Wound J. 2014, 11, 730–734. 19. Biocompatibility Index of Antiseptic Agents by Parallel Assessment of Antimicrobial Activity and Cellular Cytotoxicity; Müller, G.; Kramer, A. J. Antimicrob. Chemother. 2008, 61, 1281–1287. 20. Octenidine Dihydrochloride, a Modern Antiseptic for Skin, Mucous Membranes and Wounds; Hübner, N.-O.; Siebert, J.; Kramer, A. Skin Pharmacol. Physiol. 2010, 23, 244–258. 21. A Standardized Test to Assess the Impact of Different Organic Challenges on the Antimicrobial Activity of Antiseptics; Pitten, F.-A.; Werner, H.-P.; Kramer, A. J. Hosp. Infect. 2003, 55, 108–115. 22. Antiseptics and Disinfectants: Activity, Action, and Resistance; McDonnell, G.; Russell, A.D. Clin. Microbiol. Rev. 1999, 12, 147–179. 23. Справочник дезсредств. М.П. Робкая. Спирты и их использование в гигиене рук медицинского персонала, 2015. 24. ГРЛС. Инструкция по медицинскому применению Калия йодида 25. ГРЛС. Листок вкладыш — информация для пациента.Бетадин 26. Evaluation of Short Exposure Times of Antimicrobial Wound Solutions against Microbial Biofilms: From In Vitro to In Vivo; Johani, K.; Malone, M.; Jensen, S.O.; Dickson, H.G.; Gosbell, I.B.; Hu, H.; Yang, Q.; Schultz, G.; Vickery, K. J. Antimicrob. Chemother. 2018, 73, 494–502. 27. An Asian Perspective on Povidone Iodine in Wound Healing; Bigliardi, P.; Langer, S.; Cruz, J.J.; Kim, S.W.; Nair, H.; Srisawasdi, G. Dermatology 2017, 233, 223–233. 28. Polymeric Iodophors: Preparation, Properties, and Biomedical Applications; Makhayeva, D.N.; Irmukhametova, G.S.; Khutoryanskiy, V.V. Rev. J. Chem. 2020, 10, 40–57. 29. Povidone-Iodine in Wound Healing and Prevention of Wound Infections; Gmur, M.K.; Karpiński, T.M. Eur. J. Biol. Res. 2020, 10, 232–239. 30. ГРЛС. Инструкция по применению лекарственного препарата Калия перманганат. 31. ГРЛС. Инструкция по применению лекарственного препарата Перекись водорода 32. ГРЛС. Инструкция по медицинскому применению лекарственного препарата ХлоргексидинStandardized Comparison of Antiseptic Efficacy of Triclosan, PVP–Iodine, Octenidine Dihydrochloride, Polyhexanide and Chlorhexidine Digluconate; Koburger, T.; Hübner, N.-O.; Braun, M.; Siebert, J.; Kramer, A. J. Antimicrob. Chemother. 2010, 65, 1712–1719. 34. ГРЛС. Инструкция по медицинскому применению лекарственного препарата Мирамистин 35. The antiseptic Miramistin: a review of its comparative in vitro and clinical activity; Ali Osmanov et al. FEMS Microbiology Reviews, fuaa012, 44, 2020, 399–417. 36. Octenidine's Efficacy: A Matter of Interpretation or the Influence of Experimental Setups?; Vejzovic D, Iftic A, Ön A, Semeraro EF, Malanovic N. Antibiotics (Basel). 2022 Nov 19;11(11):1665. 37. Octenidine exposure was not associated with reduced octenidine susceptibility of meticillin-resistant Staphylococcus aureus in an extended-care facility in Singapore; Y.W. Tang, P.Y. Hon, J. Tan, B.F. Poh, B. Ang, A. Chow. Journal of Hospital Infection, Volume 149, 2024, Pages 104-107. 38. Инструкция по медицинскому применению препарата МестаМидин-сенс. 39. In Vitro Evaluation of Novel Antimicrobial Coatings for Surgical Sutures Using Octenidine; Obermeier, A.; Schneider, J.; Föhr, P.; Wehner, S.; Kühn, K.-D.; Stemberger, A.; Schieker, M.; Burgkart, R. BMC Microbiol. 2015, 15, 186. 40. Effectiveness and Tissue Compatibility of a 12-Week Treatment of Chronic Venous Leg Ulcers with an Octenidine Based Antiseptic--a Randomized, Double-Blind Controlled Study; Vanscheidt, W.; Harding, K.; Téot, L.; Siebert, J. Int. Wound J. 2012, 9, 316–323. 41. Kampf, G. Antiseptic Stewardship; Springer: Berlin/Heidelberg, Germany; New York, NY, USA, 2018. 42. Consensus on Wound Antisepsis: Update 2018; Kramer, A.; Dissemond, J.; Kim, S.; Willy, C.; Mayer, D.; Papke, R.; Tuchmann, F.; Assadian, O. Skin Pharmacol. Physiol. 2018, 31, 28–58. 43. Sopata, M.; Jawień, A.; Mrozikiewicz-Rakowska, B.; Augusewicz, Z.; Bakowska, M.; Samson, I.; Gabriel, M.; Grzela, T.; Karpiński, T.; Kuberka, I.; et al. Guidelines for local management of uninfected wounds, wounds at risk of infection and infected wounds—An overview of the available antimicrobial substances used in the treatment of wounds. Recommendations of the Polish Wound Treatment Society. Leczenie Ran 2020, 17, 1–21. 44. Opinion on Polyaminopropyl Biguanide (PHMB)—Submission III. 90. Available online: https://hal.archives-ouvertes.fr/hal-01493478 (accessed on 10 November 2021). 45. Инструкция по медицинскому применению лекарственного препарата Лавасепт 46. https://clck.ru/3PEKqZ